Multiple sites of type II site ligand (Luteolin and BMHPC) regulation of gene expression in PC-3 cells

International Journal of Biomedical Science

Volumn 8, Issue 4, 2012, Pages 219-232

  Markaverich, Barry M ^a   Vijjeswarapu, Mary ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

BMHPC; C FOS; Luteolin; P21; Prostate cancer; SiRNA knockdown; Type II sites

Indexed keywords

2,6 BIS[[3 METHOXY 4 HYDROXYPHENYL]METHYLENE] CYCLOHEXANONE; BINDING PROTEIN; CELL DIVISION CYCLE PROTEIN 25A; CYCLIN A2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E2; CYCLOHEXANONE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEINSH3 DOMAIN BINDING PROTEIN; HISTONE H4; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; POLO LIKE KINASE 1; PROTEIN; PROTEIN C FOS; PROTEIN P21; PROTEIN P27; RNA; SMALL INTERFERING RNA; SOS PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CELL STRAIN DU 145; CELL STRAIN LNCAP; CELL STRAIN PC 3; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY; EPIGENETICS; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TYPE II ESTRADIOL BINDING SITE;

EID: 84871967669     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Clark JH, Markaverich B, Upchurch S, Eriksson H, et al. Nuclear binding of the estrogen receptor: heterogeneity of sites and uterotropic response. Adv. Exp. Med. Biol. 1979; 117: 17-46.
2. Eriksson H, Upchurch S, Hardin JW, Peck EJ, Jr., et al. Heterogeneity of Estrogen Receptors in the Cytosol and Nuclear Fractions of the Rat Uterus. Biochem. Biophys. Res. Commun. 1978; 81 (1): 1-7.
3. Markaverich BM, Clark JH. Two binding sites for estradiol in rat uterine nuclei: relationship to uterotropic response. Endocrinology. 1979; 105 (6): 1458-1462.
4. Markaverich BM, Schauweker TH, Gregory RR, Varma M, et al. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones. Cancer Res. 1992; 52 (9): 2482-2488.
5. Syne JS, Markaverich BM, Clark JH, Panko WB. Estrogen binding sites in the nucleus of normal and malignant human tissue: characteristics of the multiple nuclear binding sites. Cancer Res. 1982; 42 (11): 4449-4454.
6. McKenna N, Lanz RB, O'Malley BW. Nuclear Receptor Coregulators: Cellular and Molecular Biology. Endocrine Reviews. 1999; 20 (3): 321-344.
7. Clark JH, Markaverich BM. Relationships between type I and II estra diol binding sites and estrogen induced responses. J. Steroid Biochem. 1981; 15: 49-54.
8. Ho S, Yu M. Selective Increase in Type II Estrogen-binding Sites in the Dysplastic Dorsolateral Prostates of Noble Rats. Cancer Research. 1993; 53: 528-532.
9. Ho S, Viccione T, Yu M. In vitro and In vivo Inhibition of Nuclear Type II Estrogen Binding Sites in the Dorsolateral Prostate of Noble Rats. J. of Steroid Biochemistry and Molecular Biology. 1993; 46 (4): 489-495.
10. Ho SM, Yu M. Hormonal regulation of nuclear type II estrogen binding sites in the dorsolateral prostate of noble rats. J. Steroid Biochemistry and Molecular Biology. 1995; 52 (3): 233-238.
11. Ho SM, Leav I, Merk FB, Kwan PW, et al. Induction of Aypical Hyperplasia, Apoptosis, and Type II Estrogen-Binding Sites in the Ventral Prostates of Noble Rats Treated with Testosterone and Pharmacologic Doses of Estradiol-17 Beta. Lab Investigation. 1995; 73 (3): 356-365.
12. Watson CS, Medina D, Clark JH. Characterization of progesterone receptors, estrogen receptors and estrogen (type ii)-binding sites in the hormone-independent variant of the mxt-3590 mouse mammary tumor. Endocrinology. 1982; 107 (1): 1432-1437.
13. Markaverich BM, Roberts RR, Alejandro M, Clark JH. The effect of low dose continuous exposure to estradiol on the estrogen receptor (type I) and nuclear type II sites. Endocrinology. 1984; 114 (3): 814-820.
14. Markaverich BM, Gregory RR, Alejandro MA, Clark JH, et al. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites. J. Biol. Chem. 1988; 263 (15): 7203-7210.
15. Markaverich BM, Roberts RR, Finney RW, Clark JH. Preliminary characterization of an endogenous inhibitor of [3H]estradiol binding in rat uterine nuclei. J. Biol. Chem. 1983; 258 (19): 11663-11671.
16. Markaverich BM, Roberts RR, Alejandro MA, Clark JH. An endogenous inhibitor of [3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues. Cancer Res. 1984; 44 (4): 1515-1519.
17. Adlercreutz H, Mousavi Y, Hockerstedt K. Diet and Breast Cancer. Acta. Oncologica. 1992; 31: 175-181.
18. Severson RK, Nomura AMY, Grove JS, Stemmermann GN. A Prostpective Study of Demographics, Diet, and Prostate Cancer Among Men of Japanese Ancestory in Hawaii. Cancer Res. 1989; 49: 1857-1860.
19. Steinmets KA, Potter JD. Food-Group Consumption and Colon Cancer in Adelaide Case-Control Study I. Vegetables and Fruit. Int. J. Cancer. 1993; 53: 711-719.
20. Markaverich BM, Roberts RR, Alejandro MA, Johnson GA, et al. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J. Steroid Biochem. 1988; 30 (1-6): 71-78.
21. Markaverich BM, Gregory RR, Alejandro M, Kittrell FS, et al. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res. 1990; 50 (5): 1470-1408.
22. Markaverich BM, Alejandro MA. Bioflavonoids, Type II [3H]Estradiol Binding Sites and Prostatic Cancer Cell Proliferation. International J. of Oncology. 1997; 11: 1311-1319.
23. Markaverich BM, Alejandro MA. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation. Int. J. Oncol. 1998; 12 (5): 1127-1135.
24. Markaverich BM, Gregory RR, Alejandro MA, Varma RS, et al. Estrogen regulation of methyl p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth. J. Steroid Biochem. 1989; 33 (5): 867-876.
25. Maybruck WM, Markaverich BM. Partial purification and characterization of methyl-p-hydroxyphenyllactate esterase in rat uterine cytosol. Steroids. 1997; 62 (3): 321-330.
26. Markaverich BM, Shoulars K, Alejandro MA. Nuclear type II [3H] estradiol binding site ligands: inhibition of ER-positive and ER-negative cell proliferation and c-Myc and cyclin D1 gene expression. Steroids. 2006; 71 (10): 865-874.
27. Carbone A, Ranelletti F, Rinelli A, Vecchio F, et al. Type II Estrogen Receptors in the Papillary Cystic Tumor of the Pancreas. Am. J. Cancer Research. 1989; 92: 572-576.
28. Piantelli M, Ricci R, Larocca L, Capelli A, et al. Type II Estrogen Binding Sites in Human Colorectal Carcinoma. J. Clin. Path. 1990; 43: 1004-1006.
29. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, et al. Type II Estrogen Binding Sites in a Lymphoblastoid Cell Line and Growth Inhibitory Effects of Estrogen, Anti-Estrogen and Bioflavonoids. Int. J. Cancer. 1990; 46: 1112-1116.
30. Leone G. Quercetin and the growth of leukemic progenitors. Leukemia & Lymphoma. 1996; 23: 49-53.
31. Shoulars K, Alejandro M, Thomson T, Markaverich B. Preliminary Identification of Rat Uterine Nuclear Type II [3H]Estradiol Binding Sites as Histone H4. Abstract, Annual Endocrine Society Meeting. Denver: Colorodo State University; 2001 June, 2002 Contract No.: Document Number.
32. Shoulars K, Rodrigues MA, Crowley JR, Turk J, et al. Nuclear type II [3H]estradiol binding sites: a histone H3-H4 complex. J. Steroid Biochem. Mol. Biol. 2005; 96 (1): 19-30.
33. Shoulars K, Rodriguez MA, Crowley J, Turk J, et al. Reconstitution of the type II [3H]estradiol binding site with recombinant histone H4. J. Steroid Biochem. Mol. Biol. 2006; 99 (1): 1-8.
34. Markaverich B, Shoulars K, Rodriguez M. Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells. Internation Journal of Biomedical Research. 2011; 7 (2): 101-111. PMCID: 3127207.
35. Shoulars K, Rodriguez MA, Thompson T, Markaverich BM. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin. J. Steroid Biochem. Mol. Biol. 2010; 118 (1-2): 41-50. PMCID: 2818318.
36. Sharma RK, Chalam KV. In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line. Acta. Ophthalmol. 2009; 87 (6): 618-622.
37. Markaverich BM, Vijjeswarapu M, Shoulars K, Rodriguez M. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells. J. Steroid Biochem. Mol. Biol. 2010; 122 (4): 219-231. PMCID: 2949446.
38. Markaverich BM, Varma M, Densmore CL, Schauweker TH, et al. Nuclear Type II [3H]Estradiol Binding Sites in MCF-7 Human Breast Cancer Cells: Binding Interactions with 2,6-Bis([3,4-dihydroxyphenyl]-methylene)-cyclohexanone Esters and Inhibition of Cell Proliferation. Internat. J. Oncol. 1994; 4: 1291-1300.
39. Chan QK, Lam HM, Ng CF, Lee AY, et al. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ. 2010.
40. Gry M, Rimini R, Stromberg S, Asplund A, et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics. 2009; 10: 365. PMCID: 2728742.
41. Maybruck WM, Markaverich BM. Detection of Esterase Activity in Nondenaturing NuSieve Agarose Gels from the Reliant Gel System. Resolutions, FMC BioProducts. 1995; 11 (1): 7.
42. Pagliacci MC, Spinozzi F, Migliorati G, Fumi G, et al. Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur. J. Cancer. 1993; 29A: 1573-1577.
43. Pagliacci M, Smacchia M, Migliorati G, Grignani F, et al. Growth-Inhibitory Effects of the Natural Phytoestrogen Genistein in MCF-7 Human Breast Cancer Cells. European J. of Cancer. 1994; 30A (11): 1675-1682.
44. Piantelli M, Rinelli A, Macri E, Maggiano N, et al. Type II estrogen binding sites and antiproliferative activity of quercetin in human menigiomas. Cancer. 1993; 71 (1): 193-198.
45. Piantelli M, Maggiano N, Ricci R, Larocca LM, et al. Tamoxifen and Quercetin Interact with Type II Estrogen Binding Sites and Inhibit the Growth of Human Melanoma Cells. J. of Investigative Dermatology. 1995; 105 (2): 248-253.
46. Scambia G, Ranelletti F, Benedetti Panici P, Piantelli M, et al. Inhibitory effects of quercetin on OVCA 433 cells and the presence of type II oestrogen binding sites in primary ovarian tumors and cultured cells. Br. J. Cancer. 1990; 62: 942-946.
47. Scambia G, Ranelletti FO, Benedetti Panici P, et al. Quercetin Inhibits the Growth of Multidrug-Resistant Estrogen-Receptor Negative MCF-7 Human Breast Cancer Cell Line Expressing Type II Estrogenbinding Sites. Cancer Chemother Pharmacol. 1991; 28: 255-258.
48. Scambia G, Ranelletti FO, Panici B, Piantelli M, et al. Quercetin Induces Type-II Estrogen-Binding Sites in Estrogen-Receptor-Negative (MDA-MB-231) and Estrogen-Receptor-Positive (MCF-7) Human Breast Cancer Cell Lines. International Journal of Cancer. 1993; 54: 462-466.
49. Shoulars K, Brown T, Alejandro MA, Crowley J, et al. Identification of nuclear type II [(3)H]estradiol binding sites as histone H4. Biochem. Biophys. Res. Commun. 2002; 296 (5): 1083-1090.
50. Iizuka M, MM S. Functional consequences of histone modifications. Current Opinions in Genetics and Development. 2003; 13: 154-160.
51. Koch CM, Andrews RM, Flicek P, Dillon SC, et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res. 2007; 17 (6): 691-707.
52. Lee HS, Park MH, Yang SJ, Jung HY, et al. Gene expression analysis in human gastric cancer cell line treated with trichostatin A and S-adenosyl-L-homocysteine using cDNA microarray. Biol. Pharm Bull. 2004; 27 (10): 1497-503.
53. Fang J, Zhou Q, Shi XL, Jiang BH. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis. 2007; 28 (3): 713-723.
54. Wu B, Zhang Q, Shen W, Zhu J. Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. Mol. Cell Biochem. 2008; 313 (1-2): 125-132.
55. Bauerschmidt C, Pollok S, Kremmer E, Nasheuer HP, et al. Interactions of human Cdc45 with the Mcm2-7 complex, the GINS complex, and DNA polymerases delta and epsilon during S phase. Genes Cells. 2007; 12 (6): 745-758.
56. Karlsson C, Katich S, Hagting A, Hoffmann I, et al. Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J. Cell Biol. 1999; 146 (3): 573-584. PMCID: 2150562.
57. Sanchez Y, Wong C, Thoma RS, Richman R, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science. 1997; 277 (5331): 1497-1501.
58. Wang F, Zhang R, Beischlag TV, Muchardt C, et al. Roles of Brahma and Brahma/SWI2-related gene 1 in hypoxic induction of the erythropoietin gene. J. Biol. Chem. 2004; 279 (45): 46733-46741.
59. Chen YJ, Lee MT, Yao HC, Hsiao PW, et al. Crucial role of estrogen receptor-alpha interaction with transcription coregulators in folliclestimulating hormone and transforming growth factor beta1 up-regulation of steroidogenesis in rat ovarian granulosa cells. Endocrinology. 2008; 149 (9): 4658-4668.
60. Gong J, Zhu J, Goodman OB, Jr., Pestell RG, et al. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene. 2006; 25 (14): 2011-2021.
61. Onate S, Tsai SY, Tsai MJ, O'Malley BW. Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily. Science. 1995; 270: 1354-1357.